Revvity AlphaLISA SureFire Ultra Human Phospho-BCR-ABL1 Tyr245 Detection Kit, 10,000 Assay Points

BCR-ABL1 is an oncogenic fusion protein resulting from the Philadelphia chromosome translocation t(9;22), which joins the BCR gene on chromosome 22 to the ABL1 tyrosine kinase gene on chromosome 9. The fusion protein exhibits constitutive tyrosine kinase activity independent of normal regulatory mechanisms, driving uncontrolled cell proliferation through activation of RAS/MAPK, PI3K/AKT, and JAK/STAT pathways. BCR-ABL1 is the causative driver in chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemias (ALL). The kinase domain of BCR-ABL1 is the target of tyrosine kinase inhibitors including imatinib, dasatinib, and nilotinib, which have revolutionized CML treatment and transformed it from a fatal disease to a manageable chronic condition. Resistance mutations in the kinase domain, particularly T315I, have driven development of next-generation inhibitors such as ponatinib.

The AlphaLISA SureFire Ultra Human Phospho-BCR-ABL1 Tyr245 Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-BCR-ABL1 Tyr245 in cellular lysates, using Alpha Technology.

Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• High-throughput screening for preclinical studies